Teva Pharmaceutical Industries Ltd. will make a generic version of Vytorin (ezetimibe and simvastatin) available in America.
With Teva already holding the largest portfolio of generic products which have been approved by the FDA, the generic option of Vytorin adds one more statin drug to its portfolio.
Teva's generic medicine portfolio counts in at almost 600, and the company also has over 100 first-to-files that are pending approval in the U.S. Even more impressive, however, is that one out of every six generic prescriptions in the U.S. is satisfied by a Teva product.
The generic Vytorin tablets which are being made by Teva are specifically designed for lowering of low density lipoprotein cholesterol and increasing high density lipoprotein cholesterol, in addition to lowing the fat levels in blood.
Vytorin's annual sales were an estimate $678 million in the U.S., based on IMS information in February.
Alerts Sign-up